• Lay-Myint Yoshida, Michiko Toizumi, Hien Anh Thi Nguyen, Billy J Quilty, Le Thuy Lien, Le Huy Hoang, Chihiro Iwasaki, Mizuki Takegata, Noriko Kitamura, Monica L Nation, Jason Hinds, Kevin van Zandvoort, Belinda D Ortika, Eileen M Dunne, Catherine Satzke, Hung Thai Do, Kim Mulholland, Stefan Flasche, and Duc-Anh Dang.
• From the Department of Pediatric Infectious Diseases, Institute of Tropical Medicine (L.-M.Y., M. Toizumi, C.I., M. Takegata), the Department of Global Health, School of Tropical Medicine and Global Health (L.-M.Y., M. Toizumi), and Nagasaki University Graduate School of Biomedical Science (L.-M.Y.), Nagasaki University, Nagasaki, and the National Institute of Infectious Diseases, Tokyo (N.K.) - both in Japan; the Department of Bacteriology, National Institute of Hygiene and Epidemiology, Hanoi (H.A.T.N., L.H.H., D.-A.D.), and the Department of Bacteriology, Pasteur Institute, Nha Trang (L.T.L., H.T.D.) - both in Vietnam; the Department of Infectious Disease Epidemiology (B.J.Q., K.Z., K.M., S.F.) and the Centre for Mathematical Modelling of Infectious Diseases (B.J.Q., K.Z., S.F.), London School of Hygiene and Tropical Medicine, and the Institute for Infection and Immunity, St. George's University (J.H.) - both in London; the Department of Infection, Immunity, and Global Health, Murdoch Children's Research Institute (M.L.N., B.D.O., E.M.D., C.S., K.M.), and the Department of Paediatrics, University of Melbourne (C.S., K.M.), Melbourne, VIC, and the Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC (C.S.) - all in Australia; and the Center for Global Health, Charité-Universitätmedizin Berlin, Berlin (S.F.).
• N. Engl. J. Med. 2024 Nov 28; 391 (21): 199220021992-2002.

BackgroundAfter pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs.MethodsWe investigated whether a single primary dose and booster dose (1p+1) of the 10-valent PCV (PCV10) would be noninferior to alternative dose schedules in sustaining control of carriage of pneumococcal serotypes included in the vaccine. In Nha Trang, Vietnam, an area in which PCV had not been used previously, a PCV10 catch-up campaign was conducted in which the vaccine was offered to children younger than 3 years of age, after which a cluster-randomized trial was conducted in which children received PCV10 at 2, 3, and 4 months of age (3p+0 group); at 2, 4, and 12 months of age (2p+1 group); at 2 and 12 months of age (1p+1 group); or at 12 months of age (0p+1 group). Annual carriage surveys in infants (4 to 11 months of age) and toddlers (14 to 24 months of age) were conducted from 2016 through 2020. The primary end point was protection against carriage of vaccine serotypes, evaluated in a noninferiority analysis in the 1p+1 group as compared with the 2p+1 and 3p+0 groups, 3.5 years after vaccine introduction (noninferiority margin, 5 percentage points). Noninferiority of the 0p+1 schedule was also evaluated.ResultsIn 2016, before the introduction of PCV10, vaccine-serotype carriage was found in 160 of 1363 infants (11.7%); in 2020, vaccine-serotype carriage was found in 6 of 333 (1.8%), 5 of 340 (1.5%), and 4 of 313 (1.3%) infants in the 1p+1, 2p+1, and 3p+0 groups, respectively, indicating noninferiority of 1p+1 to 2p+1 (difference, 0.3 percentage points; 95% confidence interval [CI], -1.6 to 2.2) and to 3p+0 (difference, 0.5 percentage points; 95% CI, -1.4 to 2.4). Similarly, 1p+1 was noninferior to 2p+1 and 3p+0 for protection against vaccine-serotype carriage among toddlers. In 2016, carriage of serotype 6A was found in 99 of 1363 infants (7.3%); in 2020, it was found in 12 of 333 (3.6%), 10 of 340 (2.9%), and 3 of 313 (1.0%) infants in the 1p+1, 2p+1, and 3p+0 groups, respectively. The 0p+1 schedule was also noninferior to the other three dose schedules among infants and toddlers, although cross-protection against serotype 6A was less common than with the other vaccination schedules. No PCV10-associated severe adverse effects were observed.ConclusionsA reduced vaccination schedule involving a single primary dose and booster dose of PCV10 was noninferior to alternative schedules in protecting against vaccine-serotype carriage in infants and toddlers. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02961231.).Copyright © 2024 Massachusetts Medical Society.

35 keywords...

hide…